Press Kit: 2026 Multidisciplinary Radiopharmaceutical Therapy Symposium
The inaugural Multidisciplinary Radiopharmaceutical Therapy Symposium will take place February 17-18, 2026, in Palm Desert, California. This new, two-day meeting brings together experts from oncology, nuclear medicine, radiology and related fields to share the most up-to-date research and education in the rapidly expanding area of radiopharmaceutical treatments for cancer and other diseases.
Radiopharmaceuticals are a type of specialized, systemic medicine where doctors inject targeted radiation to destroy tumor cells while limiting exposure to surrounding tissues. As the number of approved agents and the demand for these treatments grow, clinical teams and health systems are increasingly seeking guidance on building and sustaining RPT services for their communities. This new symposium will offer practical strategies and multidisciplinary perspectives to support both early adopters and teams scaling their programs.
Program highlights include keynote remarks from Stephen M. Hahn, MD, FASTRO, Chief Executive Officer and Board Chair of Nucleus RadioPharma and former Commissioner of the U.S. Food and Drug Administration, and Johannes Czernin, MD, Chief of the Ahmanson Translational Imaging Division at UCLA Health. For more information, read our media advisory.
Embargo Policy and Access to Abstracts
All abstracts to be presented at the 2026 Multidisciplinary Radiopharmaceutical Therapy Symposium are embargoed until 8:00 a.m. Pacific time, Tuesday, February 17, 2026. The embargo policy applies to all abstracts regardless of whether information is obtained from another source.
Embargo violations by media professionals may result in suspension of credentials at the symposium as well as future meetings and may also impact the ability to receive advance media materials for future meetings. Embargo violations by abstract authors and/or sponsors may result in removal of the abstract from the scientific program. Abstract authors are responsible for notifying financial and other sponsors about this embargo policy.
The full text of the abstracts selected for oral and poster presentation will be available online at the start of the meeting. Abstracts also will be published in a supplement of the International Journal of Radiation Oncology • Biology • Physics.
Press Registration
ASTRO provides complimentary meeting registration to credentialed news professionals representing media organizations for the express purpose of gathering news and information to produce editorial coverage of the symposium. Complimentary registration is also open to public information officers from educational institutions, government agencies and nonprofit cancer research organizations presenting research at the symposium.
Exhibitors are not permitted to register as press unless they can provide proof of editorial assignment from an accredited news organization that meets the above criteria. Public relations, marketing and/or advertising representatives, financial analysts, book publishers and book authors, and individuals from communications, print or online promotion services are welcome to register as regular attendees, however, they are not permitted to register as press. ASTRO reserves the right to bar from this and future meetings any journalist who misuses press privileges to engage in activities other than journalistic pursuits.
Contact ASTRO’s media relations team to request press registration. Applicants may be asked to provide media credentials, a letter of assignment and/or bylined articles.
For More Information
Contact ASTRO’s media relations team for help with media inquiries or interview requests.
Visit the symposium website for meeting and program details.
Connect with ASTRO on social media.
Find doctor-vetted patient information from ASTRO's experts.
Read more about ASTRO's efforts to advance the science and practice of radiopharmaceutical therapy, such as our publications and partnerships with industry.
